Lacrimal implants and related methods

• US 10,238,535 B2
• Filed: 02/23/2010
• Issued: 03/26/2019
• Est. Priority Date: 02/23/2009
• Status: Active Grant

• Current Assignee: Mati Therapeutics, Inc
• Original Assignee: Mati Therapeutics, Inc
• Inventors: Rapacki, Alan R., Rubinchik, Valery, Kjellbotn, Charles Richard
• Primary Examiner(s): Zimbouski, Ariana
• Application Number:
  US12/710,855
• Publication Number:
  US 20100274204A1
• Time in Patent Office: 3,318 Days
• Field of Search: 604 8, 604285
• CPC Class Codes: A61F 2250/0003 having an inflatable pocket filled with fluid, e.g. liquid or gas
• CPC Class Codes: A61F 9/00772 Apparatus for restoration of tear ducts
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants

Abstract

Lacrimal implants and related methods providing secure, wedgable retention within a lacrimal punctum and associated canaliculus of an eye are disclosed. The lacrimal implants can comprise an implant body configured for at least partial insertion through the lacrimal punctum and into the canaliculus. The implant body can include first and second portions, and can extend from a proximal end of the first portion defining a longitudinal proximal axis to a distal end of the second portion defining a longitudinal distal axis. The implant body can be configured such that, when implanted using an integral dilator, an angled intersection exists between the proximal and distal axes. In this way, at least a portion of the implant body can be biased against at least a portion of the lacrimal canaliculus located at or more distal to a canalicular curvature, thereby retaining an implanted position of the lacrimal implant using anatomical structures.

Claims

1. A lacrimal implant for insertion into a lacrimal canaliculus, comprising:

an implant body, comprising first and second portions, the implant body non-linearly extending from a proximal end portion positionable within a vertical section of the lacrimal canaliculus to a distal end portion positionable within a horizontal section of the lacrimal canaliculus and having an intermediate portion therebetween, the proximal end of the first portion defining a longitudinal proximal axis and the distal end of the second portion defining a longitudinal distal axis, the first portion including a cavity;

a drug insert disposed in the cavity, the drug insert including a polymeric matrix, a therapeutic agent dissolved or dispersed in the polymeric matrix, and an impermeable sheath body disposed over at least a portion of the polymeric matrix to define at least one insert exposed surface located at or near the proximal end of the first portion implant body;

the intermediate portion partially extending in a first direction toward the proximal end portion, partially extending in a second direction toward the distal end portion, and partially extending in a third direction along the longitudinal distal axis to form a retention element, configured to bias against a portion of a lacrimal canaliculus ampulla wherein the third direction is perpendicular to the first direction of the intermediate portion, such that, when implanted in the lacrimal canaliculus, the implant body directionally biases laterally against at least a portion of the lacrimal canaliculus located at or more distal to a canalicular curvature; and

a graspable projection extending at least partially from the proximal end of the first portion, the graspable projection including an inward-extending retaining lip that overhangs a cavity to secure the drug insert within the cavity of the first portion, wherein the inward-extending retaining lip overhangs a proximal surface of the drug insert, when fully seated in the cavity, thereby securing a position of the insert,

wherein the implant body inhibits fluid flow into and through the lacrimal canaliculus.

2. The lacrimal implant of claim 1, wherein the graspable projection extending at least partially from the proximal end of the first portion, is configured to seat against or near a lacrimal punctum when the implant body is implanted.

3. The lacrimal implant of claim 1, wherein the therapeutic agent is a non steroidal anti-inflammatory (NSAID).

4. The lacrimal implant of claim 1, wherein the therapeutic agent is an anti-glaucoma drug.

5. The lacrimal implant of claim 1, wherein the implant is used to treat glaucoma, pre- and post-surgical ocular treatments, dry eye, anti-eye allergy, anti-infective, post-surgical inflammation or pain, respiration-related disorders, allergies, inner ear disorders, dizziness, migraines, systemic disorders, hypertension, cholesterol management, pulmonary disorders or immunological disorders.

6. The lacrimal implant of claim 1, wherein the retention element comprises a flat hull-like shape.

7. The lacrimal implant of claim 1, wherein the retention element projects proximally about 0.44 millimeters from an intersection of the first and second portions of the implant body.

8. The lacrimal implant of claim 1, wherein the retention element further comprises an insertion-facilitating depression graspable by an insertion tool.

9. The lacrimal implant of claim 1, wherein an outer surface slope of the second portion is between about 1 degree to about 10 degrees with respect to the longitudinal distal axis.

10. The lacrimal implant of claim 1, wherein the first direction and second direction of the intermediate portion comprise an angle that is from about 45 degrees to about 135 degrees.

11. The lacrimal implant of claim 1, wherein the implant body comprises silicone, polyurethane or acrylic.

12. The lacrimal implant of claim 1, wherein the implant body comprises a biocompatible colorant.

13. The lacrimal implant of claim 1, wherein the graspable projection is ovoid shaped.

14. A lacrimal implant insertable into a lacrimal canaliculus, comprising:

an implant body, including first and second portions, the implant body extending from a proximal end of the first portion to a distal end of the second portion, the proximal end of the first portion defining a longitudinal proximal axis and the distal end of the second portion defining a longitudinal distal axis;

the first portion including a cavity extending inward from the proximal end of the first portion, a drug insert disposed in the cavity of the first portion to provide a sustained therapeutic agent release to an eye, wherein the drug insert comprises the therapeutic agent, a matrix and an impermeable sheath providing at least one exposed surface to deliver a sustained release of the therapeutic agent;

a graspable projection extending at least partially from the proximal end of the first portion, the graspable projection including an inward-extending retaining lip that overhangs a cavity to secure the drug insert within the cavity of the first portion, wherein the inward-extending retaining lip overhangs a proximal surface of the drug insert, when fully seated in the cavity, thereby securing a position of the insert,

wherein a proximal end of the second portion comprises a retention element configured to bias against a portion of a lacrimal canaliculus ampulla; and

the implant body configured such that, when implanted in the lacrimal canaliculus, an angled intersection exists between the proximal axis and the distal axis for biasing at least a portion of the implant body against at least a portion of the lacrimal canaliculus located at or more distal to a canalicular curvature.

15. The lacrimal implant of claim 14, wherein the graspable projection extending at least partially from the proximal end of the first portion, is configured to seat against or near a lacrimal punctum when the implant body is implanted.

16. The lacrimal implant of claim 14, wherein the therapeutic agent is a non steroidal anti-inflammatory (NSAID).

17. The lacrimal implant of claim 14, wherein the therapeutic agent is an anti-glaucoma drug.

18. The lacrimal implant of claim 14, wherein the implant is used to treat glaucoma, pre- and post-surgical ocular treatments, dry eye, anti-eye allergy, anti-infective, post-surgical inflammation or pain, respiration-related disorders, allergies, inner ear disorders, dizziness, migraines, systemic disorders, hypertension, cholesterol management, pulmonary disorders or immunological disorders.

19. The lacrimal implant of claim 14, wherein the retention element comprises a flat hull-like shape.

20. The lacrimal implant of claim 14, wherein the retention element projects proximally from the angled intersection about 0.44 millimeters.

21. The lacrimal implant of claim 14, wherein the retention element further comprises an insertion-facilitating depression graspable by an insertion tool.

22. The lacrimal implant of claim 14, wherein an outer surface slope of the second portion is between about 1 degree to about 10 degrees with respect to the longitudinal distal axis.

23. The lacrimal implant of claim 14, wherein the angled intersection is from about 45 degrees to about 135 degrees.

24. The lacrimal implant of claim 14, wherein the second portion tapers from a first diameter at a proximal end of the second portion to a second diameter at the distal end of the second portion.

25. The lacrimal implant of claim 14, wherein the implant body comprises silicone, polyurethane or acrylic.

26. The lacrimal implant of claim 14, wherein the implant body comprises a biocompatible colorant.

27. The lacrimal implant of claim 14, wherein the graspable projection is ovoid shaped.

28. A lacrimal implant insertable into a lacrimal canaliculus, comprising:

an implant body, including first and second portions, the implant body extending from a proximal end of the first portion to a distal end of the second portion, the proximal end of the first portion defining a longitudinal proximal axis and the distal end of the second portion defining a longitudinal distal axis;

the first portion including a cavity extending inward from the proximal end of the first portion, a drug insert disposed in the cavity of the first portion to provide a sustained therapeutic agent release to an eye, wherein the drug insert comprises the therapeutic agent, a matrix and an impermeable sheath providing at least one exposed surface to deliver a sustained release of the therapeutic agent;

an ovoid graspable projection extending at least partially from the proximal end of the first portion, the graspable projection including an inward-extending retaining lip that overhangs a cavity to secure a drug insert within the first portion, wherein the inward-extending retaining lip overhangs a proximal surface of the drug insert, when fully seated in the cavity, thereby securing a position of the insert;

wherein a proximal end of the second portion comprises a retention element configured to bias against a portion of a lacrimal canaliculus ampulla; and

the implant body configured such that, when implanted in the lacrimal canaliculus, an angled intersection exists between the proximal axis and the distal axis for biasing at least a portion of the implant body against at least a portion of the lacrimal canaliculus located at or more distal to a canalicular curvature.